Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
146.35
+0.74 (+0.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
June 21, 2024
How much Sarepta can hope to earn from Elevidys is unclear due to its cost, $3 million, and that it's not a cure. Yet SRPT stock is surging.
Via
InvestorPlace
Exposures
Product Safety
Apple To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday
June 21, 2024
Via
Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
June 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 21, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 9 Analysts
June 14, 2024
Via
Benzinga
12 Analysts Have This To Say About Sarepta Therapeutics
May 20, 2024
Via
Benzinga
What Analysts Are Saying About Sarepta Therapeutics Stock
May 02, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
June 21, 2024
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Via
InvestorPlace
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
June 21, 2024
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.
Via
Benzinga
Exposures
Product Safety
Wall Street Looks Set For Modestly Lower Start Ahead Of Key Data, Tech Stocks Muted In Premarket: Analyst Says 'Bearish Sentiment Has Become Understandably Quiet'
June 21, 2024
Wall Street is on track for a lackluster open after the S&P 500’s back-to-back record performances in the first two sessions of the week. The major index futures were all uniformly lower in early...
Via
Benzinga
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
June 20, 2024
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease.
Via
Investor's Business Daily
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
June 20, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
June 19, 2024
Via
Benzinga
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
June 13, 2024
Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom.
Via
Investor's Business Daily
Exposures
Product Safety
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
June 06, 2024
These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside
Via
InvestorPlace
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
May 31, 2024
Via
Benzinga
Why Sarepta Therapeutics Stock Is Rising Today
May 30, 2024
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months
May 28, 2024
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge.
Via
Benzinga
Exposures
Product Safety
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 28, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 24, 2024
Via
Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
May 23, 2024
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy.
Via
InvestorPlace
Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir
May 22, 2024
Jim Cramer likes Enbridge Inc. (NYSE: ENB), says Lazard, Inc. (NYSE: LAZ) is a good buy, and Advanced Drainage Systems, Inc. (NYSE: WMS) is an incredible infrastructure play. He also mentions Jacobs...
Via
Benzinga
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
May 20, 2024
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD.
Via
Investor's Business Daily
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
May 04, 2024
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.
Via
InvestorPlace
Exposures
Product Safety
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
May 03, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday
May 02, 2024
Via
Benzinga
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 01, 2024
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
May 01, 2024
SRPT earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
May 01, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.